AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

2026-02-04 15:39:52 ET

When I last assessed AbbVie Inc. ( ABBV ), I was focused on VENCLEXTA, an oncology drug that the company was hoping to expand into myelodysplastic syndrome, or MDS. As it turned out, the Phase 3 registration-enabling VERONA trial flunked, leaving the blockbuster drug “stuck” in CLL, SLL, and AML. Such are the realities of drug development. For a company the size of AbbVie, the MDS disappointment was “merely a blip on [its] radar.”...

Read the full article on Seeking Alpha

For further details see: